382 related articles for article (PubMed ID: 16870798)
1. Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.
Rieg G; Spellberg B; Schwartz J; Fu Y; Edwards JE; Sheppard DC; Ibrahim AS
Antimicrob Agents Chemother; 2006 Aug; 50(8):2895-6. PubMed ID: 16870798
[No Abstract] [Full Text] [Related]
2. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
3. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
4. Nebulized liposomal amphotericin B and combined systemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal mitochondrial disorder.
Castagnola E; Moresco L; Cappelli B; Cuzzubbo D; Moroni C; Lanino E; Faraci M
J Chemother; 2007 Jun; 19(3):339-42. PubMed ID: 17594932
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
Chandrasekar PH; Cutright JL; Manavathu EK
Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
[TBL] [Abstract][Full Text] [Related]
6. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.
Alvarez CA; Wiederhold NP; McConville JT; Peters JI; Najvar LK; Graybill JR; Coalson JJ; Talbert RL; Burgess DS; Bocanegra R; Johnston KP; Williams RO
J Infect; 2007 Jul; 55(1):68-74. PubMed ID: 17360039
[TBL] [Abstract][Full Text] [Related]
7. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
8. An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections.
Myint H; Kyi AA; Winn RM
J Antimicrob Chemother; 1998 Mar; 41(3):424-6. PubMed ID: 9578177
[No Abstract] [Full Text] [Related]
9. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
10. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
[TBL] [Abstract][Full Text] [Related]
11. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.
Graybill JR; Kaster SR
Am Rev Respir Dis; 1984 Feb; 129(2):292-5. PubMed ID: 6364905
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
Ho KM; Duff O; Chambers D; Murray R
Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
[TBL] [Abstract][Full Text] [Related]
13. Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B.
Khan MA; Ahmad N; Moin S; Mannan A; Wajahul H; Pasha ST; Khan A; Owais M
FEMS Immunol Med Microbiol; 2005 Jun; 44(3):269-76. PubMed ID: 15907448
[TBL] [Abstract][Full Text] [Related]
14. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
15. [An experimental study of the therapeutic effect of interleukin-2 and interleukin-12 with and without amphotericin B on pulmonary fungal infection].
Zhang CR; Tang YC; Kawakami K; Zhang TT; Zhang KX; Zhu JX
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr; 27(4):234-6. PubMed ID: 15144612
[TBL] [Abstract][Full Text] [Related]
16. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
Imai J; Singh G; Fernandez B; Clemons KV; Stevens DA
J Antimicrob Chemother; 2005 Jul; 56(1):166-71. PubMed ID: 15917284
[TBL] [Abstract][Full Text] [Related]
18. Reversible dilated cardiomyopathy related to amphotericin B therapy.
Danaher PJ; Cao MK; Anstead GM; Dolan MJ; DeWitt CC
J Antimicrob Chemother; 2004 Jan; 53(1):115-7. PubMed ID: 14657095
[TBL] [Abstract][Full Text] [Related]
19. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
20. Aerosolized antifungal prophylaxis: the winds of change?
Perfect JR
Clin Infect Dis; 2008 May; 46(9):1409-11. PubMed ID: 18419444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
